Bloomlife
Bloomlife provides a cellular-enabled, FDA-cleared remote patient monitoring platform for high-risk pregnancies, targeting OB/GYNs, maternal-fetal medicine specialists, and US health systems with reimbursable blood pressure, blood glucose, and fetal monitoring.
- Company typePrivate
- Founded2014
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Bloomlife does
Bloomlife is a women's health technology company that has built a remote patient monitoring (RPM) platform for high-risk pregnancies. Founded in 2014 by Eric Dy and Julien Penders after Dy experienced a high-risk pregnancy in his own family, the company develops cellular-enabled, FDA-cleared medical devices for blood pressure, blood glucose, and patch-based fetal monitoring that transmit data directly to providers without requiring patient WiFi or smartphone apps. The core product, Bloomlife Connects, integrates these device modules with a Health Screening component (PHQ-9, EPDS, social determinants of health assessments), an AI-based digital biomarker for labor onset detection, configurable smart notifications, and native EMR integration.
The company targets OB/GYNs, maternal-fetal medicine specialists, women's health practices, and health systems in the United States, with engineering and clinical study operations in Liège, Belgium and Eindhoven, Netherlands. Its business model is reimbursement-driven: the RPM program is offered to providers at no upfront cost and no commitment, with device costs bundled into existing CPT-coded remote patient monitoring reimbursement covered by 19 in-network commercial payers plus Medicaid. Customer references include UCHealth, Ochsner Health System, Oregon Health Science University, Valley Perinatal Services, Unified Women's Healthcare, and Advantia Health.
Bloomlife has raised approximately $29M cumulatively across disclosed rounds from 2015 through September 2024, including a $12.9M round in September 2024, with investors including SOSV HAX, Plug and Play, Kapor Capital, Noshaq (Meusinvest), SFPIM, and RH Capital. The company holds 15 patents and 19 peer-reviewed publications supporting its clinical evidence base, has received FDA 510(k) clearance for its fetal monitor (K222327), and maintains SOC 2 Type II and HIPAA compliance for enterprise-grade deployment.
Bloomlife firmographics
Firmographics- Name
- Bloomlife
- Legal name
- Bloomlife, Inc.
- Website
- https://bloom-life.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Bloomlife provides a cellular-enabled, FDA-cleared remote patient monitoring platform for high-risk pregnancies, targeting OB/GYNs, maternal-fetal medicine specialists, and US health systems with reimbursable blood pressure, blood glucose, and fetal monitoring.
- Ownership category
- akta.pro rank
Bloomlife industry classification
Industry- Product category
- Maternal Health Remote Monitoring
- SIC
- Services-Home Health Care Services (8082)
- akta.pro primary industry
- Maternal & High-Risk Pregnancy Remote Monitoring (BP, glucose, fetal/uterine monitoring) (HLALAFAG)
- akta.pro secondary industries
- Maternal, Neonatal & Pediatric Remote Monitoring (HLACAPAG), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables) (HLAHACAF)
Keywords
Where Bloomlife is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Bloomlife business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Remote Patient Monitoring Reimbursement: Bloomlife's primary revenue stream comes from Remote Patient Monitoring reimbursement covered by Medicaid and commercial payers using existing CPT codes. The program includes cellular-enabled FDA-cleared monitoring devices where the cost of devices (blood pressure cuff and blood glucose device) is included in the remote patient monitoring reimbursement with no additional costs charged to the practice or patient.
- Equity Securities Offering: SEC Form D filing indicates an exempt offering of securities raising approximately $14.9 million with equity securities and pooled investment fund interests.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | RPM Program for Healthcare Providers |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Bloomlife product offering
Product offeringCore offering
Bloomlife provides a connected care platform, Bloomlife Connects, for remote patient monitoring of high-risk pregnancies. The offering combines FDA-cleared cellular-enabled medical devices for blood pressure, blood glucose, and patch-based fetal monitoring with cloud-based analytics, EMR integration, customizable clinical protocols, and AI-based digital markers for labor detection. The program is sold to healthcare providers and is reimbursable under existing CPT codes for remote patient monitoring.
Product overview
Bloomlife offers Bloomlife Connects, a comprehensive connected care platform for remote monitoring of high-risk pregnancies. The platform integrates multiple monitoring modules including Blood Pressure RPM (cellular-enabled, FDA-cleared blood pressure monitoring), Blood Glucose RPM (continuous glucose monitoring and finger stick support), Fetal Monitoring (patch-based home fetal non-stress testing with FDA 510(k) clearance), and Health Screening (PHQ-9 and EPDS mental health assessments). These modules work together to enable healthcare providers to assess maternal-fetal health outside the office, with automated data capture, configurable clinical protocols, smart notifications, and EMR integration.
Differentiator
Problem solved
Functional benefit
Products and services
- Bloomlife Connects A comprehensive connected care platform that enables healthcare providers to remotely monitor high-risk pregnant patients. Includes FDA-cleared cellular-enabled blood pressure and blood glucose monitoring devices, the world's first patch-based home fetal monitoring solution (FDA 510(k) #K222327), and digital health screening assessments (PHQ-9, EPDS). Features cloud-based analytics, customizable care escalation protocols, smart notifications, native EMR integration, and AI-based digital markers for labor detection. Designed for healthcare providers including OB/GYN practices, MFM specialists, and health systems, and is reimbursable using existing CPT codes for remote patient monitoring.
Quantifiable outcome
- 260% improvement in adherence to home blood pressure screening with Bloomlife Connects compared to standard of care
- +8 more outcomes
Companies that use Bloomlife
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Bloomlife technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature6 records
Bloomlife partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered advisory and customer.
- March of DimesadvisoryMarch of Dimes Chief Medical Officer Amanda Williams, MD, MPH serves as an advisor to Bloomlife, providing expertise in women's health and maternal care improvement.
- Valley Perinatal ServicescustomerValley Perinatal Services is both a customer and advisory partner, with MFM Medical Director Ravi Gunatilake serving as a medical advisor. The practice uses Bloomlife Connects for remote monitoring of high-risk patients.
- Louisiana Perinatal Quality CollaborativeadvisoryMedical Director Veronica Gillispie-Bell, MD, MAS serves as a strategic advisor, bringing expertise in perinatal quality improvement and maternal health outcomes.
- OrganonadvisoryCharlotte Owens, MD, Head of Medical Affairs and Outcomes Research at Organon, serves as an advisor bringing pharmaceutical and women's health industry expertise.
Scale indicators15 records
Recent moves6 records
Expansion highlights6 records
Bloomlife competitors and assessment
Company assessmentDirect peers
- Babyscripts: Babyscripts is a direct competitor offering a maternal remote patient monitoring platform for OB/GYN practices, including blood pressure monitoring, weight tracking, and virtual care. It targets the same provider customer base and reimbursement model as Bloomlife.
- HeraMED: HeraMED develops remote fetal and maternal monitoring solutions, including at-home NST and contraction monitoring devices. It competes directly with Bloomlife in connected maternal-fetal monitoring for high-risk pregnancies.
- Vivify Health (by Optum): Vivify Health provides a remote patient monitoring platform with cellular-enabled devices, EMR integration, and condition-specific pathways. While not maternal-specific, its technology stack and reimbursement-driven RPM model are highly comparable to Bloomlife Connects.
Broad incumbents
- Philips (Philips Avent and BioTelemetry): Philips offers fetal monitoring hardware, maternal care solutions, and a broader remote patient monitoring portfolio through BioTelemetry. It overlaps with Bloomlife on maternal monitoring and RPM but as part of a much wider medtech portfolio.
- GE Healthcare: GE Healthcare provides in-clinic and ambulatory fetal monitoring solutions and broader hospital-grade patient monitoring. It competes in the same clinical category as Bloomlife's fetal monitoring module but at a much larger, enterprise-hospital scale.
Emerging players
- Ovia Health (by Labcorp): Ovia Health provides digital maternity and women's health programs to employers and health plans, including engagement, coaching, and some remote monitoring components. It is comparable to Bloomlife in serving the same maternal population but with a software/engagement-led approach rather than FDA-cleared devices.
- Maven Clinic: Maven Clinic is a digital women's and family health platform offering virtual care across preconception, pregnancy, postpartum, and pediatrics, including partnerships with health plans and employers. It overlaps with Bloomlife in serving high-risk pregnant patients but delivers care through a virtual clinic model rather than FDA-cleared monitoring devices.
- iHealth Labs: iHealth Labs offers FDA-cleared cellular-enabled blood pressure monitors, glucose meters, and other connected devices used in consumer and RPM settings. It is comparable to Bloomlife on the hardware and cellular connectivity side but without an integrated maternal-care platform.
- CareSimple: CareSimple is a remote patient monitoring vendor that provides cellular-enabled devices, EMR integration, and condition-specific programs for providers, including chronic disease management. It is comparable to Bloomlife in its RPM-as-a-service model targeting providers under CPT-based reimbursement.
- MindChild Medical: MindChild Medical develops non-invasive fetal monitoring devices for clinical and potentially home use. It is comparable to Bloomlife in fetal heart rate monitoring technology but focuses on the in-clinic/hospital segment rather than a full RPM platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Bloomlife social profiles
Digital presenceBloomlife compliance and trust
Trust signalCompliance3 records
Bloomlife financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bloomlife leadership team
Management profileNumber of profiles
Profiles8 records
Bloomlife funding detail
Funding detailFunding overview
Funding rounds5 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bloomlife M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bloomlife
What does Bloomlife do?
Bloomlife provides a connected care platform, Bloomlife Connects, for remote patient monitoring of high-risk pregnancies. The offering combines FDA-cleared cellular-enabled medical devices for blood pressure, blood glucose, and patch-based fetal monitoring with cloud-based analytics, EMR integration, customizable clinical protocols, and AI-based digital markers for labor detection. The program is sold to healthcare providers and is reimbursable under existing CPT codes for remote patient monitoring.
Is Bloomlife a public or private company?
Bloomlife is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bloomlife founded?
Bloomlife was founded in 2014. It employs 11 to 50 people.
Where is Bloomlife based?
Bloomlife is headquartered in San Francisco, United States, in the North America region.
How does Bloomlife make money?
Two revenue lines are on record. Remote Patient Monitoring Reimbursement is the primary driver. The others are equity Securities Offering.
Who are Bloomlife's main competitors?
Direct peers on record are Babyscripts, HeraMED and Vivify Health (by Optum). Broad incumbents are Philips (Philips Avent and BioTelemetry) and GE Healthcare. Emerging players are Ovia Health (by Labcorp), Maven Clinic, iHealth Labs, CareSimple and MindChild Medical.
Does Bloomlife have an API?
No public API is recorded for Bloomlife.
What industry is Bloomlife in?
Bloomlife's product category is Maternal Health Remote Monitoring. Its primary akta.pro industry code is HLALAFAG, Maternal & High-Risk Pregnancy Remote Monitoring (BP, glucose, fetal/uterine monitoring), with a secondary code of HLACAPAG, Maternal, Neonatal & Pediatric Remote Monitoring. Its SIC code is 8082.